Glycosaminoglycan replacement therapy in preventing women’s recurrent urinary tract infections?: A systematic review and meta-analysis
Abstract
The aim of this study is to systematically review the published literature and pool the data to evaluate the effectiveness of glycosaminoglycans (GAGs) replacement therapy in preventing women’s recurrent urinary tract infections (rUTIs). A systematic search of PubMed was performed to identify comparative and randomized controlled trials that compared the efficacy of GAG replacement therapy with control groups (placebo/antibiotics/standard therapy) in preventing rUTI in women. The evaluated outcomes included risk of rUTI, rUTI episodes per patient-year, time to urinary tract infection recurrence, pelvic pain and urgency/frequency, and the quality of life (Short Form-36 questionnaire). The Cochrane Collaboration Review Manager software (RevMan, version 5.4) was used for statistical analysis. Seven trials, including 2 randomized control studies and 5 retrospective comparative trials, met the inclusion criteria and were enrolled into our meta-analysis. A total of 702 patients were included in the analysis. Five studies adopted intravesical instillations and 2 used oral-administered hyaluronic acid. The synthesized results revealed that GAG replacement therapy significantly reduced the risk of rUTI (odds ratio: 0.31), reduced urinary tract infection-associated symptoms on pelvic pain and urgency/frequency scores (WMD: −6.70), and contributed to nonsignificant influence in quality of life, prolongation of time to rUTI, and the risk of rUTI per patient-year. In conclusion, the…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 702 participants or records.
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.